drug: thalidomide
- Clinical class: sedative hypnotic, antiangiogenesis, antinauseant, anti-leprosy, immunomodulatory
- Action: central nervous system depressant
- CSA schedule: none
- DEA number: none
- CDER thalidomide information
- MEDLINEplus® Drug Information
U.S. Preparations:
- Thalomid® (Celgene) FDA approved for treatment of:
7.16.1998 erythema nodosa leprosum (leprosy, ENL)
5.25.2006 newly diagnosed multiple myeloma in combination with dexametasone
U.S. Prescribing Information
Preparations Outside U.S.:
- Kevadon®, Synovir®